FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 495 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Clinical Benefit of Pembrolizumab in Patients with Previously Treated Advanced Clear... March 4, 2025 EMA Recommends Granting a Marketing Authorisation for Fruquintinib May 13, 2024 Quality of Life Is Maintained with First-line Nivolumab Plus Ipilimumab in... December 10, 2020 2-Time Cancer Survivor Warns Against Breast Implants After 4 Doctors Missed... June 25, 2019 Load more HOT NEWS Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... Mediterranean Diet Associated with a Higher Probability of Response in Patients... Stealing Strategies from Cancerous T Cells May Boost Immunotherapy 3 Steps to Making the Right Decisions for You During Cancer:...
